WO1997013877A1 - Mesure de profils d'expression genique pour evaluer la toxicite - Google Patents

Mesure de profils d'expression genique pour evaluer la toxicite Download PDF

Info

Publication number
WO1997013877A1
WO1997013877A1 PCT/US1996/016342 US9616342W WO9713877A1 WO 1997013877 A1 WO1997013877 A1 WO 1997013877A1 US 9616342 W US9616342 W US 9616342W WO 9713877 A1 WO9713877 A1 WO 9713877A1
Authority
WO
WIPO (PCT)
Prior art keywords
population
microparticles
tag
compound
oligonucleotide
Prior art date
Application number
PCT/US1996/016342
Other languages
English (en)
Inventor
Sydney Brenner
Original Assignee
Lynx Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1995/012791 external-priority patent/WO1996012014A1/fr
Priority claimed from PCT/US1996/009513 external-priority patent/WO1996041011A1/fr
Application filed by Lynx Therapeutics, Inc. filed Critical Lynx Therapeutics, Inc.
Priority to AU77175/96A priority Critical patent/AU7717596A/en
Priority to US09/269,911 priority patent/US6228589B1/en
Priority to JP51524097A priority patent/JP4105764B2/ja
Priority to EP96940238A priority patent/EP0931165A4/fr
Publication of WO1997013877A1 publication Critical patent/WO1997013877A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00497—Features relating to the solid phase supports
    • B01J2219/005—Beads
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/0054—Means for coding or tagging the apparatus or the reagents
    • B01J2219/00572—Chemical means
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/0061—The surface being organic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00612—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00623—Immobilisation or binding
    • B01J2219/0063—Other, e.g. van der Waals forces, hydrogen bonding
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00632—Introduction of reactive groups to the surface
    • B01J2219/00637—Introduction of reactive groups to the surface by coating it with another layer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00639—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium
    • B01J2219/00641—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium the porous medium being continuous, e.g. porous oxide substrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00646—Making arrays on substantially continuous surfaces the compounds being bound to beads immobilised on the solid supports
    • B01J2219/00648—Making arrays on substantially continuous surfaces the compounds being bound to beads immobilised on the solid supports by the use of solid beads
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00659—Two-dimensional arrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00722—Nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B70/00—Tags or labels specially adapted for combinatorial chemistry or libraries, e.g. fluorescent tags or bar codes

Definitions

  • the invention relates generally to methods for detecting and monitoring phenotypic changes in in vitro and in vivo systems for assessing and/or determining the toxicity of chemical compounds, and more particularly, the invention relates to a method for detecting and monitoring changes in gene expression patterns in in vitro and in vivo systems for determining the toxicity of drug candidates.
  • Toxicity assessment is an area where such improvements may be made, for both drug development and for assessing the environmental, health, and safety effects of new compounds in general.
  • the toxicity of a compound is determined by administering the compound to one or more species of test animal under controlled conditions and by monitoring the effects on a wide range of parameters.
  • the parameters include such things as blood chemistry, weight gain or loss, a variety of behavioral patterns, muscle tone, body temperature, respiration rate, lethality, and the like, which collectively provide a measure of the state of health of the test animal.
  • Such tests may be designed to assess the acute, prolonged, or chronic toxicity of a compound.
  • acute tests involve administration of the test chemical on one occasion.
  • the period of observation of the test animals may be as short as a few hours, although it is usually at least 24 hours and in some cases it may be as long as a week or more.
  • prolonged tests involve administration of the test chemical on multiple occasions.
  • the test chemical may be administered one or more times each day, irregularly as when it is incorporated in the diet, at specific times such as during pregnancy, or in some cases regularly but only at weekly intervals.
  • the experiment is usually conducted for not less than 90 days in the rat or mouse or a year in the dog.
  • the chronic toxicity tests are those in which the test chemical is administered for a substantial portion of the lifetime of the test animal. In the case of the mouse or rat, this is a period of 2 to 3 years. In the case of the dog, it is for 5 to 7 years.
  • An object of the invention is to provide a new approach to toxicity assessment based on an examination of gene expression patterns, or profiles, in in vitro or in vivo test systems.
  • Another object of the invention is to provide a database on which to base decisions concerning the toxicological properties of chemicals, particularly drug candidates.
  • a further object of the invention is to provide a method for analyzing gene expression patterns in selected tissues of test animals.
  • a still further object of the invention is to provide a system for identifying genes which are differentially expressed in response to exposure to a test compound.
  • Another object of the invention is to provide a rapid and reliable method for correlating gene expression with short term and long term toxicity in test animals.
  • Another object of the invention is to identify genes whose expression is predictive of deleterious toxicity.
  • the invention achieves these and other objects by providing a method for massively parallel signature sequencing of genes expressed in one or more selected tissues of an organism exposed to a test compound.
  • An important feature of the invention is the application of novel DNA sorting and sequencing methodologies that permit the formation of gene expression profiles for selected tissues by determining the sequence of portions of many thousands of different polynucleotides in parallel. Such profiles may be compared with those from tissues of control organisms at single or multiple time points to identify expression patterns predictive of toxicity.
  • the sorting methodology of the invention makes use of oligonucleotide tags that are members of a minimally cross-hybridizing set of oligonucleotides.
  • sequences of oligonucleotides of such a set differ from the sequences of every other member of the same set by at least two nucleotides. Thus, each member of such a set cannot form a duplex (or triplex) with the complement of any other member with less than two mismatches.
  • Complements of oligonucleotide tags of the invention may comprise natural nucleotides or non-natural nucleotide analogs.
  • tag complements are attached to solid phase supports.
  • Such oligonucleotide tags when used with their corresponding tag complements provide a means of enhancing specificity of hybridization for sorting polynucleotides, such as cDNAs.
  • the polynucleotides to be sorted each have an oligonucleotide tag attached, such that different polynucleotides have different tags.
  • this condition is achieved by employing a repertoire of tags substantially greater than the population of polynucleotides and by taking a sufficiently small sample of tagged polynucleotides from the full ensemble of tagged polynucleotides. After such sampling, when the populations of supports and polynucleotides are mixed under conditions which permit specific hybridization of the oligonucleotide tags withtheir respective complements, identical polynucleotides sort onto particular beads or regions. The sorted populations of polynucleotides can then be sequenced on the solid phase support by a "single-base” or “base-by-base” sequencing methodology, as described more fully below.
  • the method of the invention comprises the following steps: (a) administering the compound to a test organism; (b) extracting a population of mRNA molecules from each of one or more tissues of the test organism; (c) forming a separate population of cDNA molecules from each population of mRNA molecules extracted from the one or more tissues such that each cDNA molecule of the separate populations has an oligonucleotide tag attached, the oligonucleotide tags being selected from the same minimally cross-hybridizing set; (d) separately sampling each population of cDNA molecules such that substantially all different cDNA molecules within a separate population have different oligonucleotide tags attached; (e) sorting the cDNA molecules of each separate population by specifically hybridizing the oligonucleotide tags with their respective complements, the respective complements being attached as uniform populations of substantially identical complements in spatially discrete regions on one or more solid phase supports; (f) determining the nucleotide sequence of a portion of each of the sorted
  • genes whose expression is predictive of the toxicity of a compound may be employed in conventional assays, such as reverse transcriptase polymerase chain reaction (RT-PCR) assays for gene expression.
  • RT-PCR reverse transcriptase polymerase chain reaction
  • Figure 1 is a flow chart representation of an algorithm for generating minimally cross-hybridizing sets of oligonucleotides.
  • FIG. 1 diagrammatically illustrates an apparatus for carrying out
  • oligonucleotide tags refers to an oligonucleotide to which a oligonucleotide tag specifically hybridizes to form a perfectly matched duplex or triplex.
  • the oligonucleotide tag may beselected to be either double stranded or single stranded.
  • the term "complement" is meant to encompass either a double stranded complement of a single stranded oligonucleotide tag or a single stranded complement of a double stranded oligonucleotide tag.
  • oligonucleotide as used herein includes linear oligomers of natural or modified monomers or linkages, including deoxyribonucleosides, ribonucleosides, anomeric forms thereof, peptide nucleic acids (PNAs), and the like, capable of specifically binding to a target polynucleotide by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of base pairing, base stacking, Hoogsteen or reverse Hoogsteen types of base pairing, or the like.
  • monomers are linked by phosphodiester bonds or analogs thereof to form
  • oligonucleotides ranging in size from a few monomeric units, e.g. 3-4, to several tens of monomeric units. Whenever an oligonucleotide is represented by a sequence of letters, such as "ATGCCTG,” it will be understood that the nucleotides are in 5' ⁇ 3' order from left to right and that "A” denotes deoxyadenosine, "C” denotes
  • oligonucleotides of the invention comprise the four natural nucleotides; however, they may also comprise non-natural nucleotide analogs. It is clear to those skilled in the art when oligonucleotides having natural or non-natural nucleotides may be
  • oligonucleotides consisting of natural nucleotides are required.
  • Perfectly matched in reference to a duplex means that the poly- or oligonucleotide strands making up the duplex form a double stranded structure with one other such that every nucleotide in each strand undergoes Watson-Crick basepairing with a nucleotide in the other strand.
  • the term also comprehends the pairing of nucleoside analogs, such as deoxyinosine, nucleosides with 2-aminopurine bases, and the like, that may be employed.
  • the term means that the triplex consists of a perfectly matched duplex and a third strand in which every nucleotide undergoes Hoogsteen or reverse Hoogsteen association with a basepair of the perfectly matched duplex.
  • a "mismatch" in a duplex between a tag and an oligonucleotide means that a pair or triplet of nucleotides in the duplex or triplex fails to undergo Watson-Crick and/or Hoogsteen and/or reverse Hoogsteen bonding.
  • nucleoside includes the natural nucleosides, including 2'-deoxy and 2'-hydroxyl forms, e.g. as described in Kornberg and Baker, DNA
  • nucleosides in reference to nucleosides includes synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g. described by Scheit, Nucleotide Analogs (John Wiley, New York, 1980); Uhlman and Peyman, Chemical Reviews, 90: 543-584 (1990). or the like, with the only proviso that they are capable of specific hybridization.
  • Such analogs include synthetic nucleosides designed to enhance binding properties, reduce complexity, increase specificity, and the like.
  • sequence determination or "determining a nucleotide sequence” in reference to polynucleotides includes determination of partial as well as full sequence information of the polynucleotide. That is, the term includes sequence comparisons, fingerprinting, and like levels of information about a target
  • sequence determination may be effected by identifying the ordering and locations of a single type of nucleotide, e.g. cytosines, within the target polynucleotide "CATCGC " so that its sequence is represented as a binary code, e.g. " 100101 ... " for "C-(not C)-(not C)-C-(not C)-C ... " and the like.
  • sequence determination may be effected by identifying the ordering and locations of a single type of nucleotide, e.g. cytosines, within the target polynucleotide "CATCGC " so that its sequence is represented as a binary code, e.g. " 100101 ... " for "C-(not C)-(not C)-C-(not C)-C ... " and the like.
  • complexity in reference to a population of polynucleotides means the number of different species of molecule present in the population.
  • the terms "gene expression profile,” and “gene expression pattern” which is used equivalently, means a frequency distribution of sequences of portions of cDNA molecules sampled from a population of tag-cDNA conjugates. Generally, the portions of sequence are sufficiently long to uniquely identify the cDN A from which the portion arose. Preferably, the total number of sequences determined is at least 1000; more preferably, the total number of sequences determined in a gene expression profile is at least ten thousand.
  • test organism means any in vitro or in vivo system which provides measureable responses to exposure to test compounds.
  • test organisms may be mammalian cell cultures, particularly of specific tissues, such as hepatocytes, neurons, kidney cells, colony forming cells, or the like, or test organisms may be whole animals, such as rats, mice, hamsters, guinea pigs, dogs, cats, rabbits, pigs, monkeys, and the like.
  • the invention provides a method for determining the toxicity of a compound by analyzing changes in the gene expression profiles in selected tissues of test organisms exposed to the compound.
  • the invention also provides a method of identifying toxicity markers consisting of individual genes or a group of genes that is expressed acutely and which is correlated with prolonged or chronic toxicity, or suggests that the compound will have an undesirable cross reactivity.
  • Gene expression profiles are generated by sequencing portions of cDNA molecules construction from mRNA extracted from tissues of test organisms exposed to the compound being tested.
  • tissue is employed with its usual medical or biological meaning, except that in reference to an in vitro test system, such as a cell culture, it simply means a sample from the culture.
  • Gene expression profiles derived from test organisms are compared to gene expression profiles derived from control organisms to determine the genes which are differentially expressed in the test organism because of exposure to the compound being tested.
  • sequence information of the gene expression profiles is obtained by massively parallel signature sequencing of cDNAs, which is implemented in steps (c) through (f) of the above method.
  • test organisms In toxicity testing, two groups of test organisms are usually employed: one group serves as a control and the other group receives the test compound in a single dose (for acute toxicity tests) or a regimen of doses (for prolonged or chronic toxicity tests). Since in most cases, the extraction of tissue as called for in the method of the invention requires sacrificing the test animal, both the control group and the group receiving compound must be large enough to permit removal of animals for sampling tissues, if it is desired to observe the dynamics of gene expression through the duration of an experiment.
  • the volume administered by the oral route should not exceed 0.005 ml per gram of animal. Even when aqueous or physiological saline solutions are used for parenteral injection the volumes that are tolerated are limited, although such solutions are ordinarily thought of as being innocuous.
  • intravenous LD 50 of distilled water in the mouse is approximately 0.044 ml per gram and that of isotonic saline is 0.068 ml per gram of mouse.
  • the methods usually involve aerosolization or nebulization of fluids containing the compound.
  • the agent to be tested is a fluid that has an appreciable vapor pressure
  • it may be administered by passing air through the solution under controlled temperature conditions. Under these conditions, dose is estimated from the volume of air inhaled per unit time, the temperature of the solution, and the vapor pressure of the agent involved. Gases are metered from reservoirs. When particles of a solution are to be administered, unless the particle size is less than about 2 ⁇ m the particles will not reach the terminal alveolar sacs in the lungs.
  • a variety of apparatuses and chambers are available to perform studies for detecting effects of irritant or other toxic endpoints when they are administered by inhalation.
  • the preferred method of administering an agent to animals is via the oral route, either by intubation or by incorporating the agent in the feed.
  • two or more species should be employed that handle the test compound as similarly to man as possible in terms of metabolism, absorption, excretion, tissue storage, and the like.
  • multiple doses or regimens at different concentrations should be employed to establish a dose-response relationship with respect to toxic effects.
  • the route of administration to the test animal should be the same as, or as similar as possible to, the route of administration of the compound to man. Effects obtained by one route of administration to test animals are not a priori applicable to effects by another route of administration to man.
  • food additives for man should be tested by admixture of the material in the diet of the test animals.
  • Acute toxicity tests consist of administering a compound to test organisms on one occasion.
  • the purpose of such test is to determine the symptomotology consequent to administration of the compound and to determine the degree of lethality of the compound.
  • the initial procedure is to perform a series of range-finding doses of the compound in a single species. This necessitates selection of a route of administration, preparation of the compound in a form suitable for administration by the selected route, and selection of an appropriate species.
  • initial acute toxicity studies are performed on either rats or mice because of their low cost, their availability, and the availability of abundant toxicologic reference data on these species.
  • Prolonged toxicity tests consist of administering a compound to test organisms repeatedly, usually on a daily basis, over a period of 3 to 4 months.
  • the available routes of administration are limited because the route selected must be suitable for repeated administration without inducing harmful effects.
  • blood, urine, and perhaps other samples, should be taken repeatedly without inducing significant harm to the test animals.
  • the gene expression profiles are obtained in conjunction with the measurement of the traditional toxicologic parameters, such as listed in the table below:
  • Oligonucleotide tags are members of a minimally cross-hybridizing set of oligonucleotides.
  • the sequences of oligonucleotides of such a set differ from the sequences of every other member of the same set by at least two nucleotides. Thus, each member of such a set cannot form a duplex (or triplex) with the complement of any other member with less than two mismatches.
  • Complements of oligonucleotide tags may comprise natural nucleotides or non-natural nucleotide analogs.
  • tag complements are attached to solid phase supports.
  • Such oligonucleotide tags when used with their corresponding tag complements provide a means of enhancing specificity of hybridization for sorting, tracking, or labeling molecules, especially polynucleotides.
  • Minimally cross-hybridizing sets of oligonucleotide tags and tag complements may be synthesized either combinatorially or individually depending on the size of the set desired and the degree to which cross-hybridization is sought to be minimized (or stated another way, the degree to which specificity is sought to be enhanced).
  • a minimally cross-hybridizing set may consist of a set of individually synthesized 10-mer sequences that differ from each other by at least 4 nucleotides. such set having a maximum size of 332 (when composed of 3 kinds of nucleotides and counted using a computer program such as disclosed in Appendix Ic).
  • a minimally cross-hybridizing set of oligonucleotide tags may also be assembled combinatorially from subunits which themselves are selected from a minimally cross-hybridizing set.
  • a set of minimally cross-hybridizing 12-mers differing from one another by at least three nucleotides may be synthesized by assembling 3 subunits selected from a set of minimally cross-hybridizing 4-mers that each differ from one another by three nucleotides.
  • Such an embodiment gives a maximally sized set of 9 3 , or 729, 12-mers.
  • the number 9 is number of
  • oligonucleotides listed by the computer program of Appendix la which assumes, as with the 10-mers, that only 3 of the 4 different types of nucleotides are used.
  • the set is described as "maximal” because the computer programs of Appendices Ia-c provide the largest set for a given input (e.g. length, composition, difference in number of nucleotides between members). Additional minimally cross-hybridizing sets may be formed from subsets of such calculated sets.
  • Oligonucleotide tags may be single stranded and be designed for specific hybridization to single stranded tag complements by duplex formation or for specific hybridization to double stranded tag complements by triplex formation.
  • Oligonucleotide tags may also be double stranded and be designed for specific hybridization to single stranded tag complements by triplex formation.
  • an oligonucleotide tag When synthesized combinatorially, an oligonucleotide tag preferably consists of a plurality of subunits, each subunit consisting of an oligonucleotide of 3 to 9 nucleotides in length wherein each subunit is selected from the same minimally cross-hybridizing set.
  • the number of oligonucleotide tags available depends on the number of subunits per tag and on the length of the subunits. The number is generally much less than the number of all possible sequences the length of the tag. which for a tag n nucleotides long would be 4 n .
  • Complements of oligonucleotide tags attached to a solid phase support are used to sort polynucleotides from a mixture of polynucleotides each containing a tag.
  • Complements of the oligonucleotide tags are synthesized on the surface of a solid phase support, such as a microscopic bead or a specific location on an array of synthesis locations on a single support, such that populations of identical sequences are produced in specific regions. That is, the surface of each support, in the case of a bead, or of each region, in the case of an array, is derivatized by only one type of complement which has a particular sequence. The population of such beads or regions contains a repertoire of complements with distinct sequences.
  • the term "repertoire” means the set of minimally cross-hybridizing set of oligonucleotides that make up the tags in a particular embodiment or the corresponding set of tag complements.
  • the polynucleotides to be sorted each have an oligonucleotide tag attached, such that different polynucleotides have different tags.
  • this condition is achieved by employing a repertoire of tags substantially greater than the population of polynucleotides and by taking a sufficiently small sample of tagged polynucleotides from the full ensemble of tagged polynucleotides After such sampling, when the populations of supports and polynucleotides are mixed under conditions which permit specific hybridization of the oligonucleotide tags with their respective complements, identical polynucleotides sort onto particular beads or regions.
  • nucleotide sequences of oligonucleotides of a minimally cross-hybridizing set are conveniently enumerated by simple computer programs, such as those exemplified by programs whose source codes are listed in Appendices la and lb.
  • Program minhx of Appendix la computes all minimally cross-hybridizing sets having 4-mer subunits composed of three kinds of nucleotides.
  • Program tagN of Appendix lb enumerates longer oligonucleotides of a minimally cross-hybridizing set. Similar algorithms and computer programs are readily written for listing oligonucleotides of minimally cross-hybridizing sets for any embodiment of the invention. Table I below provides guidance as to the size of sets of minimally cross-hybridizing
  • oligonucleotide tags of a minimally cross-hybridizing set may be separately synthesized.
  • Sets containing several hundred to several thousands, or even several tens of thousands, of oligonucleotides may be synthesized directly by a variety of parallel synthesis approaches, e.g. as disclosed in Frank et al, U.S. patent 4,689,405; Frank et al, Nucleic Acids Research, 11: 4365-4377 (1983); Matson et al. Anal. Biochem., 224: 110-116 (1995); Fodor et al, International application
  • oligonucleotide tags of the invention are synthesized
  • the algorithm of Fig. 1 is implemented by first defining the characteristics of the subunits of the minimally cross-hybridizing set, i.e. length, number of base differences between members, and composition, e.g. do they consist of two, three, or four kinds of bases.
  • An initial subunit S 1 is selected and compared (120) with successive subunits S i for i-n+1 to the end of the table.
  • a successive subunit Whenever a successive subunit has the required number of mismatches to be a member of the minimally cross-hybridizing set, it is saved in a new table M n+1 (125), that also contains subunits previously selected in prior passes through step 120.
  • M 2 will contain S 1 ; in the second set of comparisons, M 3 will contain S 1 and S 2 ; in the third set of comparisons, M4 will contain S 1 , S 2 , and S 3 ; and so on.
  • comparisons in table M will be between S j and all successive subunits in M;. Note that each successive table M n+1 is smaller than its predecessors as subunits are eliminated in successive passes through step 130.
  • minimally cross-hybridizing sets comprise subunits that make approximately equivalent contributions to duplex stability as every other subunit in the set. In this way, the stability of perfectly matched duplexes between every subunit and its complement is approximately equal.
  • Guidance for selecting such sets is provided by published techniques for selecting optimal PCR primers and calculating duplex stabilities, e.g. Rychlik et al, Nucleic Acids Research, 17: 8543-8551 (1989) and 18: 6409-6412 (1990); Breslauer et al, Proc. Natl. Acad. Sci., 83: 3746-3750 (1986); Wetmur, Crit. Rev. Biochem. Mol. Biol., 26: 227-259 (1991);and the like.
  • subunits may be provided that have the same terminal nucleotides.
  • the sum of the base-stacking energies of all the adjoining terminal nucleotides will be the same, thereby reducing or eliminating variability in tag melting temperatures.
  • a "word” of terminal nucleotides may also be added to each end of a tag so that a perfect match is always formed between it and a similar terminal "word” on any other tag complement.
  • Such an augmented tag would have the form: where the primed W's indicate complements.
  • minimally cross-hybridizing sets are those whose subunits are made up of three of the four natural nucleotides.
  • the absence of one type of nucleotide in the oligonucleotide tags permits target polynucleotides to be loaded onto solid phase supports by use of the 5' ⁇ 3' exonuclease activity of a DNA polymerase.
  • the following is an exemplary minimally cross-hybridizing set of subunits each comprising four nucleotides selected from the group consisting of A, G, and T:
  • each member would form a duplex having three mismatched bases with the complement of every other member.
  • oligonucleotide tags of the invention and their complements are conveniently synthesized on an automated DNA synthesizer, e.g. an Applied
  • tags may comprise naturally occurring nucleotides that permit processing or manipulation by enzymes, while the corresponding tag complements may comprise non-natural nucleotide analogs, such as peptide nucleic acids, or like compounds, that promote the formation of more stable duplexes during sorting.
  • repertoires of oligonucleotide tags and tag complements may be generated by subunit- wise synthesis via "split and mix" techniques, e.g. as disclosed in Shortle et al. International patent application
  • the basic unit of the synthesis is a subunit of the oligonucleotide tag.
  • phosphoramidite chemistry is used and 3' phosphoramidite oligonucleotides are prepared for each subunit in a minimally cross-hybridizing set, e.g. for the set first listed above, there would be eight 4-mer 3'-phosphoramidites.
  • Synthesis proceeds as disclosed by Shortle et al or in direct analogy with the techniques employed to generate diverse oligonucleotide libraries using nucleosidic monomers, e.g.
  • oligonucleotide tags and tag complements are synthesized on a DNA synthesizer having a number of synthesis chambers which is greater than or equal to the number of different kinds of words used in the construction of the tags. That is, preferably there is a synthesis chamber corresponding to each type of word.
  • words are added nucleotide-by-nucleotide, such that if a word consists of five nucleotides there are five monomer couplings in each synthesis chamber.
  • the synthesis supports are removed from the chambers, mixed, and redistributed back to the chambers for the next cycle of word addition.
  • This latter embodiment takes advantage of the high coupling yields of monomer addition, e.g. in phosphoramidite chemistries.
  • Double stranded forms of tags may be made by separately synthesizing the complementary strands followed by mixing under conditions that permit duplex formation.
  • double stranded tags may be formed by first synthesizing a single stranded repertoire linked to a known oligonucleotide sequence that serves as a primer binding site. The second strand is then synthesized by combining the single stranded repertoire with a primer and extending with a polymerase. This latter approach is described in Oliphant et al. Gene, 44: 177-183 (1986).
  • duplex tags may then be inserted into cloning vectors along with target polynucleotides for sorting and manipulation of the target polynucleotide in accordance with the invention.
  • tag complements are employed that are made up of nucleotides that have enhanced binding characteristics, such as PNAs or oligonucleotide N3' ⁇ P 5' phosphoramidates
  • sorting can be implemented through the formation of D-loops between tags comprising natural nucleotides and their PNA or phosphoramidate complements, as an alternative to the "stripping" reaction employing the 3' ⁇ 5' exonuclease activity of a DNA polymerase to render a tag single stranded.
  • Oligonucleotide tags of the invention may range in length from 12 to 60 nucleotides or basepairs. Preferably, oligonucleotide tags range in length from 18 to 40 nucleotides or basepairs. More preferably, oligonucleotide tags range in length from 25 to 40 nucleotides or basepairs. In terms of preferred and more preferred numbers of subunits, these ranges may be expressed as follows:
  • oligonucleotide tags are single stranded and specific hybridization occurs via Watson-Crick pairing with a tag complement.
  • repertoires of single stranded oligonucleotide tags of the invention contain at least 100 members; more preferably, repertoires of such tags contain at least 1000 members; and most preferably, repertoires of such tags contain at least 10,000 members.
  • third strand association via Hoogsteen type of binding is most stable along homopyrimidine-homopurine tracks in a double stranded target.
  • base triplets form in T-A*T or C-G*C motifs (where "-" indicates Watson-Crick pairing and "*" indicates Hoogsteen type of binding); however, other motifs are also possible.
  • Hoogsteen base pairing permits parallel and antiparallel orientations between the third strand (the Hoogsteen strand) and the purine-rich strand of the duplex to which the third strand binds, depending on conditions and the composition of the strands.
  • nucleoside type e.g. whether ribose or
  • deoxyribose nucleosides are employed
  • base modifications e.g. methylated cytosine. and the like
  • Roberts et al Proc. Natl. Acad. Sci., 88: 9397-9401 (1991); Roberts et al, Science, 258: 1463-1466 (1992); Roberts et al, Proc. Natl.
  • oligonucleotide tags of the invention employing triplex hybridization are double stranded DNA and the corresponding tag complements are single stranded. More preferably, 5-methylcytosine is used in place of cytosine in the tag complements in order to broaden the range of pH stability of the triplex formed between a tag and its complement.
  • Preferred conditions for forming triplexes are fully disclosed in the above references. Briefly, hybridization takes place in concentrated salt solution, e.g. 1.0 M NaCl, 1.0 M potassium acetate, or the like, at pH below 5.5 ( or 6.5 if 5-methylcytosine is employed).
  • Hybridization temperature depends on the length and composition of the tag; however, for an 18-20-mer tag of longer, hybridization at room temperature is adequate. Washes may be conducted with less concentrated salt solutions, e.g. 10 mM sodium acetate, 100 mM MgCl 2 , pH 5.8, at room temperature. Tags may be eluted from their tag complements by incubation in a similar salt solution at pH 9.0.
  • Minimally cross-hybridizing sets of oligonucleotide tags that form triplexes may be generated by the computer program of Appendix Ic, or similar programs.
  • An exemplary set of double stranded 8-mer words are listed below in capital letters with the corresponding complements in small letters. Each such word differs from each of the other words in the set by three base pairs.
  • repertoires of double stranded oligonucleotide tags of the invention contain at least 10 members; more preferably, repertoires of such tags contain at least 100 members.
  • words are between 4 and 8 nucleotides in length for combinatorially synthesized double stranded oligonucletide tags, and oligonucleotide tags are between 12 and 60 base pairs in length. More preferably, such tags are between 18 and 40 base pairs in length.
  • Solid phase supports for use with the invention may have a wide variety of forms, including microparticles, beads, and membranes, slides, plates, micromachined chips, and the like.
  • solid phase supports of the invention may comprise a wide variety of compositions, including glass, plastic, silicon, alkanethiolate-derivatized gold, cellulose, low cross-linked and high cross-linked polystyrene, silica gel, polyamide, and the like.
  • either a population of discrete particles are employed such that each has a uniform coating, or population, of complementary sequences of the same tag (and no other), or a single or a few supports are employed with spatially discrete regions each containing a uniform coating, or population, of complementary sequences to the same tag (and no other).
  • the area of the regions may vary according to particular applications; usually, the regions range in area from several ⁇ m 2 , e.g.3-5, to several hundred ⁇ m 2 , e.g. 100-500.
  • such regions are spatially discrete so that signals generated by events, e.g. fluorescent emissions, at adjacent regions can be resolved by the detection system being employed.
  • Tag complements may be used with the solid phase support that they are synthesized on. or they may be separately synthesized and attached to a solid phase support for use, e.g. as disclosed by Lund et al, Nucleic Acids Research, 16: 10861-10880 (1988); Albretsen et al, Anal. Biochem., 189: 40-50 (1990); Wolf et al, Nucleic Acids Research, 15: 2911-2926 (1987); or Ghosh et al, Nucleic Acids Research, 15: 5353-5372 (1987).
  • tag complements are synthesized on and used with the same solid phase support, which may comprise a variety of forms and include a variety of linking moieties.
  • Such supports may comprise microparticles or arrays, or matrices, of regions where uniform populations of tag complements are synthesized.
  • microparticle supports may be used with the invention, including microparticles made of controlled pore glass (CPG), highly cross-linked polystyrene, acrylic copolymers, cellulose, nylon, dextran, latex, polyacrolein, and the like, disclosed in the following exemplary references: Meth. Enzymol., Section A, pages 11-147, vol.44 (Academic Press, New York, 1976); U.S. patents 4,678,814;
  • Microparticle supports further include commercially available nucleoside-derivatized CPG and polystyrene beads (e.g. available from Applied Biosystems, Foster City, CA);
  • linking moieties for attaching and/or synthesizing tags on microparticle surfaces are disclosed in Pon et al, Biotechniques, 6:768-775 (1988); Webb, U.S. patent 4,659,774; Barany et al, International patent application
  • tag complements may also be synthesized on a single (or a few) solid phase support to form an array of regions uniformly coated with tag complements. That is, within each region in such an array the same tag complement is synthesized.
  • Techniques for synthesizing such arrays are disclosed in McGall et al, International application PCT/US93/03767; Pease et al, Proc. Natl. Acad. Sci., 91 : 5022-5026 (1994); Southern and Maskos, International application
  • the invention is implemented with microparticles or beads uniformly coated with complements of the same tag sequence.
  • Microparticle supports and methods of covalently or noncovalently linking oligonucleotides to their surfaces are well known, as exemplified by the following references: Beaucage and Iyer (cited above); Gait, editor, Oligonucleotide Synthesis: A Practical Approach (IRL Press, Oxford, 1984); and the references cited above.
  • the size and shape of a microparticle is not critical; however, microparticles in the size range of a few. e.g. 1 -2, to several hundred, e.g.200-1000 ⁇ m diameter are preferable, as they facilitate the construction and manipulation of large repertoires of oligonucleotide tags with minimal reagent and sample usage.
  • CPG controlled-pore glass
  • polystyrene supports are employed as solid phase supports in the invention.
  • Such supports come available with base-labile linkers and initial nucleosides attached. e.g. Applied Biosystems (Foster City. CA).
  • microparticles having pore size between 500 and 1000 angstroms are employed.
  • non-porous microparticles are employed for their optical properties, which may be advantageously used when tracking large numbers of microparticles on planar supports, such as a microscope slide.
  • non-porous microparticles are the glycidal methacrylate (GMA) beads available from Bangs Laboratories (Carmel, IN).
  • GMA glycidal methacrylate
  • Such microparticles are useful in a variety of sizes and derivatized with a variety of linkage groups for synthesizing tags or tag complements.
  • linkage groups for synthesizing tags or tag complements.
  • An important aspect of the invention is the sorting and attachment of a populations of polynucleotides, e.g. from a cDNA library, to microparticles or to separate regions on a solid phase support such that each microparticle or region has substantially only one kind of polynucleotide attached.
  • a tag repertoire is employed whose complexity, or number of distinct tags, greatly exceeds the total number of mRNAs extracted from a cell or tissue sample.
  • the complexity of the tag repertoire is at least 10 times that of the polynucleotide population; and more preferably, the complexity of the tag repertoire is at least 100 times that of the polynucleotide population.
  • a protocol is disclosed for cDNA library construction using a primer mixture that contains a full repertoire of exemplary 9-word tags. Such a mixture of tag-containing primers has a complexity of 8 , or about 1.34 ⁇ 10 .
  • mRNA for library construction can be extracted from as few as 10-100 mammalian cells. Since a single mammalian cell contains about 5 ⁇ 10 copies of mRNA molecules of about 3.4 ⁇ 10 different kinds, by standard techniques one can isolate the mRNA from about 100 cells, or
  • the cDNA library construction protocol results in a population containing no more than 37% of the total number of different tags. That is, without any overt sampling step at all, the protocol inherently generates a sample that comprises 37%, or less, of the tag repertoire. The probability of obtaining a double under these conditions is about 5%, which is within the preferred range.
  • the fraction of the tag repertoire sampled is reduced to only 3.7%, even assuming that all the processing steps take place at 100% efficiency. In fact, the efficiencies of the processing steps for constructing cDNA libraries are very low, a "rule of thumb" being that good library should contain about 10 cDNA clones from mRNA extracted from 10 mammalian cells.
  • a tag-polynucleotide conjugate mixture potentially contains every possible pairing of tags and types of mRNA or polynucleotide.
  • overt sampling may be implemented by removing a sample volume after a serial dilution of the starting mixture of tag-polynucleotide conjugates. The amount of dilution required depends on the amount of starting material and the efficiencies of the processing steps, which are readily estimated.
  • Four 10-fold serial dilutions may be carried out by transferring 10 ⁇ l from the original solution into a vessel containing 90 ⁇ l of an appropriate buffer, such as TE. This process may be repeated for three additional dilutions to obtain a 100 ⁇ l solution containing 5 ⁇ 10 5 vector molecules per ⁇ l. A 2 ⁇ l aliquot from this solution yields 10 vectors containing tag-cDNA conjugates as inserts. This sample is then amplified by straight forward transformation of a competent host cell followed by culturing.
  • an appropriate buffer such as TE
  • a repertoire of oligonucleotide tags can be conjugated to a population of polynucleotides in a number of ways, including direct enzymatic ligation, amplification, e.g. via PCR, using primers containing the tag sequences, and the like.
  • the initial ligating step produces a very large population of tag-polynucleotide conjugates such that a single tag is generally attached to many different
  • substantially all in reference to attaching tags to molecules, especially polynucleotides, is meant to reflect the statistical nature of the sampling procedure employed to obtain a population of tag-molecule conjugates essentially free of doubles. The meaning of substantially all in terms of actual percentages of tag-molecule conjugates depends on how the tags are being employed.
  • substantially all means that at least eighty percent of the polynucleotides have unique tags attached. More preferably, it means that at least ninety percent of the polynucleotides have unique tags attached. Still more preferably, it means that at least ninety-five percent of the polynucleotides have unique tags attached. And, most preferably, it means that at least ninety-nine percent of the polynucleotides have unique tags attached.
  • oligonucleotides tags may be attached by reverse transcribing the mRNA with a set of primers preferably containing complements of tag sequences.
  • An exemplary set of such primers could have the following sequence (SEQ ID NO: 1): where "[W,W,W,C]9” represents the sequence of an oligonucleotide tag of nine subunits of four nucleotides each and "[W,W,W,C]" represents the subunit sequences listed above, i.e. "W” represents T or A.
  • the underlined sequences identify an optional restriction endonuclease site that can be used to release the polynucleotide from attachment to a solid phase support via the biotin, if one is employed.
  • the complement attached to a microparticle could have the form:
  • the mRNA is removed, e.g. by RNase H digestion, and the second strand of the cDNA is synthesized using, for example, a primer of the following form (SEQ ID NO: 2): where N is any one of A, T, G, or C; R is a purine-containing nucleotide, and Y is a pyrimidine-containing nucleotide.
  • This particular primer creates a Bst Y1 restriction site in the resulting double stranded DNA which, together with the Sal I site, facilitates cloning into a vector with, for example, Bam HI and Xho I sites.
  • the exemplary conjugate would have the form:
  • the polynucleotide-tag conjugates may then be manipulated using standard molecular biology techniques.
  • the above conjugate ⁇ which is actually a mixture ⁇ may be inserted into commercially available cloning vectors, e.g. Stratagene Cloning System (La Jolla, CA); transfected into a host, such as a commercially available host bacteria; which is then cultured to increase the number of conjugates.
  • the cloning vectors may then be isolated using standard techniques, e.g. Sambrook et al,
  • the Bst Y1 and Sal I digested fragments are cloned into a Bam HI-/Xho I-digested vector having the following single-copy restriction sites (SEQ ID NO: 3):
  • Tags can be conjugated to cDNAs of existing libraries by standard cloning methods.
  • cDNAs are excised from their existing vector, isolated, and then ligated into a vector containing a repertoire of tags.
  • the tag-containing vector is linearized by cleaving with two restriction enzymes so that the excised cDNAs can be ligated in a predetermined orientation.
  • the concentration of the linearized tag-containing vector is in substantial excess over that of the cDN A inserts so that ligation provides an inherent sampling of tags.
  • a general method for exposing the single stranded tag after amplification involves digesting a target polynucleotide-containing conjugate with the 5' ⁇ 3' exonuclease activity of T4 DNA polymerase. or a like enzyme. When used in the presence of a single deoxynucleoside triphosphate, such a polymerase will cleave nucleotides from 3' recessed ends present on the non-template strand of a double stranded fragment until a complement of the single deoxynucleoside triphosphate is reached on the template strand.
  • the technique may also be used to preferentially methylate interior Fok I sites of a target polynucleotide while leaving a single Fok I site at the terminus of the polynucleotide unmethylated.
  • the terminal Fok I site is rendered single stranded using a polymerase with deoxycytidine triphosphate.
  • the double stranded portion of the fragment is then methylated, after which the single stranded terminus is filled in with a DNA polymerase in the presence of all four nucleoside triphosphates, thereby regenerating the Fok I site.
  • this procedure can be generalized to
  • the polynucleotides are mixed with microparticles containing the complementary sequences of the tags under conditions that favor the formation of perfectly matched duplexes between the tags and their complements.
  • conditions that favor the formation of perfectly matched duplexes between the tags and their complements.
  • the hybridization conditions are sufficiently stringent so that only perfectly matched sequences form stable duplexes. Under such conditions the polynucleotides specifically hybridized through their tags may be ligated to the complementary sequences attached to the
  • microparticles are washed to remove polynucleotides with unligated and/or mismatched tags.
  • the density of tag complements on the microparticle surface is typically greater than that necessary for some sequencing operations. That is, in sequencing approaches that require successive treatment of the attached polynucleotides with a variety of enzymes, densely spaced polynucleotides may tend to inhibit access of the relatively bulky enzymes to the polynucleotides.
  • the polynucleotides are preferably mixed with the microparticles so that tag complements are present in significant excess, e.g. from 10:1 to 100:1, or greater, over the polynucleotides. This ensures that the density of polynucleotides on the microparticle surface will not be so high as to inhibit enzyme access.
  • the average inter-polynucleotide spacing on the microparticle surface is on the order of 30-100 nm.
  • Guidance in selecting ratios for standard CPG supports and Ballotini beads (a type of solid glass support) is found in Maskos and Southern. Nucleic Acids Research, 20: 1679-1684 (1992).
  • standard CPG beads of diameter in the range of 20-50 ⁇ m are loaded with about 10 5 polynucleotides
  • GMA beads of diameter in the range of 5-10 ⁇ m are loaded with a few tens of thousand of polynucleotides, e.g.4 ⁇ 10 4 to 6 ⁇ 10 4 .
  • tag complements are synthesized on
  • microparticles combinatorially; thus, at the end of the synthesis, one obtains a complex mixture of microparticles from which a sample is taken for loading tagged polynucleotides.
  • the size of the sample of microparticles will depend on several factors, including the size of the repertoire of tag complements, the nature of the apparatus for used for observing loaded microparticles ⁇ e.g. its capacity, the tolerance for multiple copies of microparticles with the same tag complement (i.e. "bead doubles"), and the like.
  • the following table provide guidance regarding
  • microparticle sample size microparticle diameter
  • microparticle diameter the approximate physical dimensions of a packed array of microparticles of various diameters.
  • the probability that the sample of microparticles contains a given tag complement or is present in multiple copies is described by the Poisson distribution, as indicated in the following table.
  • Specificity of the hybridizations may be increased by taking a sufficiently small sample so that both a high percentage of tags in the sample are unique and the nearest neighbors of substantially all the tags in a sample differ by at least two words
  • This latter condition may be met by taking a sample that contains a number of tag- polynucleotide conjugates that is about 0 1 percent or less of the size of the repertoire being employed. For example, if tags are constructed with eight words selected from Table II, a repertoire of 8 8 , or about 1.67 ⁇ 10 7 , tags and tag complements are produced. In a library of tag-cDNA conjugates as described above, a 0.1 percent sample means that about 16,700 different tags are present.
  • a panning step may be implemented by providing a sample of tag-cDNA conjugates each of which contains a capture moiety at an end opposite, or distal to, the oligonucleotide tag.
  • the capture moiety is of a type which can be released from the tag-cDNA conjugates, so that the tag-cDNA conjugates can be sequenced with a single-base sequencing method.
  • Such moieties may comprise biotin, digoxigenin, or like ligands, a triplex binding region, or the like.
  • a capture moiety comprises a biotin component.
  • Biotin may be attached to tag-cDNA conjugates by a number of standard techniques. If appropriate adapters containing PCR primer binding sites are attached to tag-cDNA conjugates, biotin may be attached by using a biotinylated primer in an amplification after sampling.
  • biotin may be attached after excising the tag-cDNA conjugates by digestion with an appropriate restriction enzyme followed by isolation and filling in a protruding strand distal to the tags with a DNA polymerase in the presence of biotinylated uridine triphosphate.
  • a tag-cDNA conjugate After a tag-cDNA conjugate is captured, it may be released from the biotin moiety in a number of ways, such as by a chemical linkage that is cleaved by reduction, e.g. Herman et al, Anal. Biochem., 156: 48-55 (1986), or that is cleaved photochemically, e.g. Olejnik et al, Nucleic Acids Research, 24: 361-366 (1996), or that is cleaved enzymatically by introducing a restriction site in the PCR primer.
  • the latter embodiment can be exemplified by considering the library of tag-polynucleotide conjugates described above:
  • the following adapters may be ligated to the ends of these fragments to permit amplification by PCR:
  • ACTAGT is a Spe I recognition site (which leaves a staggered cleavage ready for single base sequencing)
  • X's and Z's are nucleotides selected so that the annealing and dissociation temperatures of the respective primers are
  • the tags of the conjugates are rendered single stranded by the exonuclease activity of T4 DNA polymerase and conjugates are combined with a sample of microparticles, e.g. a repertoire equivalent, with tag complements attached.
  • the conjugates are preferably ligated to their tag complements and the loaded microparticles are separated from the unloaded microparticles by capture with avidinated magnetic beads, or like capture technique.
  • 4-5 ⁇ 10 5 cDNAs can be accumulated by pooling the released microparticles.
  • the pooled microparticles may then be simultaneously sequenced by a single-base sequencing technique.
  • a sample of at least 10 5 sequences are accumulated for the analysis of each library; and most preferably, a sample of at least 5 ⁇ 10 5 sequences are accumulated for the analysis of each library.
  • the number of sequences sampled is preferably sufficient to estimate the relative abundance of a sequence present at a frequency within the range of 0.1% to 5% with a 95% confidence limit no larger than 0.1% of the population size.
  • the present invention can be employed with conventional methods of DNA sequencing, e.g. as disclosed by Hultman et al, Nucleic Acids Research, 17: 4937-4946 (1989).
  • a DNA sequencing methodology is preferred that requires neither electrophoretic separation of closely sized DNA fragments nor analysis of cleaved nucleotides by a separate analytical procedure, as in peptide sequencing.
  • the methodology permits the stepwise identification of nucleotides, usually one at a time, in a sequence through successive cycles of treatment and detection.
  • Such methodologies are referred to herein as "single base" sequencing methods. Single base approaches are disclosed in the following references: Cheeseman, U.S.
  • a "single base" method of DNA sequencing which is suitable for use with the present invention and which requires no electrophoretic separation of DNA fragments is described in International application PCT/US95/03678. Briefly, the method comprises the following steps: (a) ligating a probe to an end of the polynucleotide having a protruding strand to form a ligated complex, the probe having a
  • a single signal generating moiety such as a single fluorescent dye, may be employed when sequencing several different target polynucleotides attached to different spatially addressable solid phase supports, such as fixed microparticles, in a parallel sequencing operation. This may be accomplished by providing four sets of probes that are applied sequentially to the plurality of target polynucleotides on the different microparticles. An exemplary set of such probes are shown below:
  • the listed probes are also shown with a single stranded poly-T tail with a signal generating moiety attached to the terminal thymidine, shown as "T*".
  • T* signal generating moiety attached to the terminal thymidine
  • such 3'-terminal nucleotides are dideoxynucleotides.
  • the probes of set lare first applied to the plurality of target polynucleotides and treated with a ligase so that target polynucleotides having a thymidine complementary to the 3' terminal adenosine of the labeled probes are ligated.
  • the unlabeled probes are simultaneously applied to minimize inappropriate ligations.
  • the locations of the target polynucleotides that form ligated complexes with probes terminating in "A" are identified by the signal generated by the label carried on the probe. After washing and cleavage, the probes of set 2 are applied.
  • target polynucleotides forming ligated complexes with probes terminating in "C" are identified by location.
  • the probes of sets 3 and 4 are applied and locations of positive signals identified. This process of sequentially applying the four sets of probes continues until the desired number of nucleotides are identified on the target polynucleotides.
  • one of ordinary skill could construct similar sets of probes that could have many variations, such as having protruding strands of different lengths, different moieties to block ligation of unlabeled probes, different means for labeling probes, and the like. Apparatus for Sequencing Populations of Polynucleotides
  • An objective of the invention is to sort identical molecules, particularly polynucleotides, onto the surfaces of microparticles by the specific hybridization of tags and their complements. Once such sorting has taken place, the presence of the molecules or operations performed on them can be detected in a number of ways depending on the nature of the tagged molecule, whether microparticles are detected separately or in "batches,” whether repeated measurements are desired, and the like.
  • the sorted molecules are exposed to ligands for binding, e.g. in drug development, or are subjected chemical or enzymatic processes, e.g. in polynucleotide sequencing. In both of these uses it is often desirable to simultaneously observe signals corresponding to such events or processes on large numbers of microparticles.
  • Microparticles carrying sorted molecules (referred to herein as "loaded"
  • microparticles lend themselves to such large scale parallel operations, e.g. as demonstrated by Lam et al (cited above).
  • light-generating signals e.g. chemiluminescent, fluorescent, or the like
  • chemiluminescent, fluorescent, or the like are employed to detect events or processes, loaded
  • microparticles are spread on a planar substrate, e.g. a glass slide, for examination with a scanning system, such as described in International patent applications
  • the scanning system should be able to reproducibly scan the substrate and to define the positions of each microparticle in a predetermined region by way of a coordinate system.
  • identification of microparticles be repeatable in successive scan steps.
  • Such scanning systems may be constructed from commercially available components, e.g. x-y translation table controlled by a digital computer used with a detection system comprising one or more photomultiplier tubes, or alternatively, a CCD array, and appropriate optics, e.g. for exciting, collecting, and sorting fluorescent signals.
  • a confocal optical system may be desirable.
  • An exemplary scanning system suitable for use in four-color sequencing is illustrated diagrammatically in Figure 5.
  • Substrate 300 e.g.
  • x-y translation table 302 which is connected to and controlled by an appropriately programmed digital computer 304 which may be any of a variety of commercially available personal computers, e.g.486-based machines or PowerPC model 7100 or 8100 available form Apple Computer (Cupertino, CA).
  • Computer software for table translation and data collection functions can be provided by commercially available laboratory software, such as Lab Windows, available from National Instruments.
  • Substrate 300 and table 302 are operationally associated with microscope 306 having one or more objective lenses 308 which are capable of collecting and delivering light to microparticles fixed to substrate 300.
  • Excitation beam 310 from light source 312, which is preferably a laser, is directed to beam splitter 314, e.g.
  • Lens 308 collects fluorescence 316 emitted from the microparticles and directs it through beam splitter 314 to signal distribution optics 318 which, in turn, directs fluorescence to one or more suitable opto-electronic devices for converting some fluorescence characteristic. e.g. intensity, lifetime, or the like, to an electrical signal.
  • Signal distribution optics 318 may comprise a variety of components standard in the art, such as bandpass filters, fiber optics, rotating mirrors, fixed position mirrors and lenses, diffraction gratings, and the like.
  • signal distribution optics 318 directs fluorescence 316 to four separate photomultiplier tubes, 330, 332, 334, and 336, whose output is then directed to pre-amps and photon counters 350, 352, 354, and 356.
  • the output of the photon counters is collected by computer 304, where it can be stored, analyzed, and viewed on video 360.
  • signal distribution optics 318 could be a diffraction grating which directs fluorescent signal 318 onto a CCD array.
  • the scanning systems should be capable of resolving closely spaced microparticles, e.g. separated by a particle diameter or less.
  • the scanning system should at least have the capability of resolving objects on the order of 10-100 ⁇ m.
  • Even higher resolution may be desirable in some embodiments, but with increase resolution, the time required to fully scan a substrate will increase; thus, in some embodiments a compromise may have to be made between speed and resolution.
  • Increases in scanning time can be achieved by a system which only scans positions where microparticles are known to be located, e.g from an initial full scan.
  • microparticle size and scanning system resolution are selected to permit resolution of fluorescently labeled microparticles randomly disposed on a plane at a density between about ten thousand to one hundred thousand microparticles per cm ⁇ .
  • loaded microparticles can be fixed to the surface of a substrate in variety of ways.
  • the fixation should be strong enough to allow the microparticles to undergo successive cycles of reagent exposure and washing without significant loss.
  • the substrate is glass, its surface may be derivatized with an alkylamino linker using commercially available reagents, e.g. Pierce Chemical, which in turn may be cross-linked to avidin, again using conventional chemistries, to form an avidinated surface.
  • Biotin moieties can be introduced to the loaded microparticles in a number of ways. For example, a fraction, e.g.
  • the cloning vectors used to attach tags to polynucleotides are engineered to contain a unique restriction site (providing sticky ends on digestion) immediately adjacent to the polynucleotide insert at an end of the polynucleotide opposite of the tag.
  • the site is excised with the polynucleotide and tag for loading onto microparticles. After loading, about 10-15 percent of the loaded polynucleotides will possess the unique restriction site distal from the microparticle surface.
  • an appropriate double stranded adaptor containing a biotin moiety is ligated to the sticky end. The resulting microparticles are then spread on the avidinated glass surface where they become fixed via the biotin-avidin linkages.
  • a mixture of probes is applied to the loaded microparticle: a fraction of the probes contain a type Us restriction recognition site, as required by the sequencing method, and a fraction of the probes have no such recognition site, but instead contain a biotin moiety at its non-ligating end.
  • the mixture comprises about 10-15 percent of the biotinylated probe.
  • the DNA when DNA-loaded microparticles are applied to a glass substrate, the DNA may nonspecifically adsorb to the glass surface upon several hours, e.g.24 hours, incubation to create a bond sufficiently strong to permit repeated exposures to reagents and washes without significant loss of microparticles.
  • such a glass substrate is a flow cell, which may comprise a channel etched in a glass slide.
  • a channel is closed so that fluids may be pumped through it and has a depth sufficiently close to the diameter of the microparticles so that a monolayer of microparticles is trapped within a defined observation region.
  • Novel polynucleotides in a cDNA library can be identified by constructing a library of cDNA molecules attached to microparticles, as described above. A large fraction of the library, or even the entire library, can then be partially sequenced in parallel. After isolation of mRNA, and perhaps normalization of the population as taught by Soares et al, Proc. Natl. Acad.
  • the following primer may by hybridized to the polyA tails for first strand synthesis with a reverse transcriptase using conventional protocols (SEQ ID NO: 1 ): where [W,W,W,C] 9 represents a tag as described above, "ACCAGCTGATC” is an optional sequence forming a restriction site in double stranded form, and "primer site” is a sequence common to all members of the library that is later used as a primer binding site for amplifying polynucleotides of interest by PCR.
  • the double stranded fragments are inserted into a cloning vector as described above and amplified.
  • the amplified library is then sampled and the sample amplified.
  • the cloning vectors from the amplified sample are isolated, and the tagged cDNA fragments excised and purified.
  • the fragments are methylated and sorted onto microparticles in accordance with the invention.
  • the cloning vector is constructed so that the tagged cDNAs can be excised with an endonuclease, such as Fok I, that will allow immediate sequencing by the preferred single base method after sorting and ligation to microparticles.
  • an endonuclease such as Fok I
  • Stepwise sequencing is then carried out simultaneously on the whole library, or one or more large fractions of the library, in accordance with the invention until a sufficient number of nucleotides are identified on each cDNA for unique
  • the library is derived from mammalian mRNA then a randomly selected sequence 14-15 nucleotides long is expected to have unique representation among the 2-3 thousand megabases of the typical mammalian genome.
  • identification of far fewer nucleotides would be sufficient for unique representation in a library derived from bacteria, or other lower organisms.
  • at least 20-30 nucleotides are identified to ensure unique representation and to permit construction of a suitable primer as described below.
  • the tabulated sequences may then be compared to known sequences to identify unique cDNAs.
  • Unique cDNAs are then isolated by conventional techniques, e.g. constructing a probe from the PCR amplicon produced with primers directed to the prime site and the portion of the cDNA whose sequence was determined. The probe may then be used to identify the cDNA in a library using a conventional screening protocol.
  • the above method for identifying new cDNAs may also be used to fingerprint mRNA populations, either in isolated measurements or in the context of a
  • Partial sequence information is obtained simultaneously from a large sample, e.g. ten to a hundred thousand, or more, of cDNAs attached to separate microparticles as described in the above method.
  • An exemplary tag library is constructed as follows to form the chemically synthesized 9-word tags of nucleotides A, G, and T defined by the formula: where "[ 4 (A,G,T)9]" indicates a tag mixture where each tag consists of nine 4-mer words of A, G, and T; and "p" indicate a 5' phosphate. This mixture is ligated to the following right and left primer binding regions (SEQ ID NO: 4 and SEQ ID NO 5):
  • the right and left primer binding regions are ligated to the above tag mixture, after which the single stranded portion of the ligated structure is filled with DNA polymerase then mixed with the right and left primers indicated below and amplified to give a tag library (SEQ ID NO: 6).
  • the underlined portion of the left primer binding region indicates a Rsr II recognition site.
  • the left-most underlined region of the right primer binding region indicates recognition sites for Bsp 120I, Apa I, and Eco O 109I, and a cleavage site for Hga I.
  • the right-most underlined region of the right primer binding region indicates the recognition site for Hga I.
  • the right or left primers may be synthesized with a biotin attached (using conventional reagents, e.g. available from Clontech Laboratories, Palo Alto, CA) to facilitate purification after amplification and/or cleavage.
  • the plasmid is cleaved with Ppu MI and Pme I (to give a Rsr Il-compatible end and a flush end so that the insert is oriented) and then methylated with DAM methylase.
  • the tag-containing construct is cleaved with Rsr II and then ligated to the open plasmid, after which the conjugate is cleaved with Mbo I and Bam HI to permit ligation and closing of the plasmid.
  • the plasmid is then amplified and isolated and used in accordance with the invention.
  • the gene expression profile of rat liver tissue is examined following administration of several compounds known to induce the expression of cytochrome P-450 isoenzymes.
  • the results obtained from the method of the invention are compared to results obtained from reverse transcriptase PCR measurements and immunochemical measurements of the cytochrome P-450 isoenzymes. Protocols and materials for the latter assays are described in Morris et al, Biochemical Pharmacology, 52: 781-792 (1996).
  • Test compounds are phenobarbital (PB), metyrapone (MET), dexamethasone (DEX), clofibrate (CLO), corn oil (CO), and ⁇ -naphthoflavone (BNF), and are available from Sigma Chemical Co. (St. Louis, MO).
  • Antibodies against specific P-450 enzymes are available from the following sources: rabbit anti-rat CYP3A1 from Human Biologics, Inc. (Phoenix, AZ); goat anti-rat CYP4A1 from Daiichi Pure Chemicals Co.
  • Animals are administered either PB (100 mg/kg), BNF (100 mg/kg), MET (100 mg/kg), DEX (100 mg/kg), or CLO (250 mg/kg) for 4 consecutive days via intraperitoneal injection following a dosing regimen similar to that described by Wang et al, Arch. Biochem. Biophys. 290: 355-361 (1991). Animals treated with H 2 O and CO are used as controls. Two hours following the last injection (day 4), animals are killed, and the livers are removed. Livers are immediately frozen and stored at -70°C.
  • Total RNA is prepared from frozen liver tissue using a modification of the method described by Xie et al, Biotechniques, 11: 326-327 (1991). Approximately 100-200 mg of liver tissue is homogenized in the RNA extraction buffer described by Xie et al to isolate total RNA. The resulting RNA is reconstituted in
  • RNA is stored in
  • RNA corresponding to about 0.5 ⁇ g of poly(A) + RNA are used to construct libraries of tag-cDNA conjugates following the protocol described in the section entitled "Attaching Tags to Polynucleotides for Sorting onto Solid Phase Supports," with the following exception: the tag repertoire is constructed from six 4-nucleotide words from Table II. Thus, the complexity of the repertoire is 8 6 or about 2.6 ⁇ 10 5 .
  • the tag-cDNA conjugate library constructed ten samples of about ten thousand clones are taken for amplification and sorting. Each of the amplified samples is separately applied to a fixed monolayer of about 10 6 10 ⁇ m diameter GMA beads containing tag complements.
  • the "sample" of tag complements in the GMA bead population on each monolayer is about four fold the total size of the repertoire, thus ensuring there is a high probability that each of the sampled tag-cDNA conjugates will find its tag complement on the monolayer.
  • the tag-cDNA conjugates of the samples are separately applied to the monolayers under conditions that permit specific hybridization only between oligonucleotide tags and tag complements forming perfectly matched duplexes.
  • Concentrations of the amplified samples and hybridization times are selected to permit the loading of about 5 ⁇ 10 4 to 2 ⁇ 10 5 tag-cDNA conjugates on each bead where perfect matches occur.
  • 9-12 nucleotide portions of the attached cDNAs are determined in parallel by the single base sequencing technique described by Brenner in International patent application PCT/US95/03678. Frequency distributions for the gene expression profiles are assembled from the sequence information obtained from each of the ten samples.
  • RT-PCRs of selected mRNAs corresponding to cytochrome P-450 genes and the constitutively expressed cyclophilin gene are carried out as described in Morris et al (cited above). Briefly, a 20 ⁇ L reaction mixture is prepared containing 1x reverse transcriptase buffer (Gibco BRL), 10 nM dithiothreitol, 0.5 nM dNTPs, 2.5 ⁇ M oligo d(T) 15 primer, 40 units RNasin (Promega, Madison, WI), 200 units RNase H-reverse transcriptase (Gibco BRL), and 400 ng of total RNA (in diethylpyrocarbonate-treated water).
  • 1x reverse transcriptase buffer Gibco BRL
  • 10 nM dithiothreitol 10 nM dithiothreitol
  • 0.5 nM dNTPs 0.5 nM dNTPs
  • 2.5 ⁇ M oligo d(T) 15 primer
  • reaction is incubated for 1 hour at 37°C followed by inactivation of the enzyme at 95°C for 5 min.
  • the resulting cDNA is stored at -20°C until used.
  • a 10 ⁇ L reaction mixture is prepared containing 10x polymerase reaction buffer, 2 mM MgCl 2 , 1 unit Taq DNA polymerase (Perkin-Elmer, Norwalk, CT), 20 ng cDNA, and 200 nM concentration of the 5' and 3' specific PCR primers of the sequences described in Morris et al (cited above).
  • PCRs are carried out in a Perkin-Elmer 9600 thermal cycler for 23 cycles using melting, annealing, and extension conditions of 94°C for 30 sec, 56°C for 1 min., and 72°C for 1 min., respectively.
  • Amplified cDNA products are separated by PAGE using 5% native gels. Bands are detected by staining with ethidium bromide.
  • nitrocellulose membranes are blocked with 2.5% BSA and immunoblotted for P-450 isoenzymes using primary monoclonal and polyclonal antibodies and secondary alkaline phosphatase conjugated anti-IgG. Immunoblots are developed with the Bio-Rad alkaline phosphatase substrate kit.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un procédé permettant d'évaluer la toxicité d'un composé dans un organisme test en mesurant les profils d'expression de gènes dans des tissus sélectionnés. Lesdits profils se mesurent par séquençage massif de signatures parallèles de banques d'ADNc obtenues à partir d'ARNm extrait des tissus sélectionnés. Les profils d'expression de gènes fournissent d'importantes informations sur les effets de l'administration d'un composé à un organisme test à la fois dans les tests de toxicité aiguë et dans les tests de toxicité prolongée et chronique.
PCT/US1996/016342 1995-10-12 1996-10-11 Mesure de profils d'expression genique pour evaluer la toxicite WO1997013877A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU77175/96A AU7717596A (en) 1995-10-12 1996-10-11 Measurement of gene expression profiles in toxicity determination
US09/269,911 US6228589B1 (en) 1996-10-11 1996-10-11 Measurement of gene expression profiles in toxicity determination
JP51524097A JP4105764B2 (ja) 1996-10-11 1996-10-11 毒性決定における遺伝子発現プロフィールの測定
EP96940238A EP0931165A4 (fr) 1995-10-12 1996-10-11 Mesure de profils d'expression genique pour evaluer la toxicite

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1995/012791 WO1996012014A1 (fr) 1994-10-13 1995-10-12 Systeme de marquage moleculaire
PCT/US1996/009513 WO1996041011A1 (fr) 1995-06-07 1996-06-06 Marqueurs oligonuclotidiques servant a trier et a identifier

Publications (1)

Publication Number Publication Date
WO1997013877A1 true WO1997013877A1 (fr) 1997-04-17

Family

ID=26789815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/016342 WO1997013877A1 (fr) 1995-10-12 1996-10-11 Mesure de profils d'expression genique pour evaluer la toxicite

Country Status (1)

Country Link
WO (1) WO1997013877A1 (fr)

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027090A1 (fr) * 1997-11-20 1999-06-03 Smithkline Beecham Corporation Procede d'evaluation des effets toxiques et pathologiques de stimuli environnementaux sur la transcription des genes
WO1999058720A1 (fr) * 1998-05-12 1999-11-18 Acacia Biosciences, Inc. Appareils, systemes et procedes quantitatifs permettant d'analyser une expression genique
WO2000012760A2 (fr) * 1998-08-28 2000-03-09 Incyte Pharmaceuticals, Inc. Marqueurs de reaction toxicologique
WO2000014273A2 (fr) * 1998-09-03 2000-03-16 Signalgene Inc. Technique de representation de differentiels genetiques et vecteur
WO2000015851A1 (fr) * 1998-09-17 2000-03-23 Curagen Corporation Classification geometrique et hierarchique fondee sur l'expression genetique
WO2000022168A1 (fr) * 1998-10-13 2000-04-20 Bioreliance Testing And Development, Inc. Evaluation de cancerogenicite
WO2000024934A1 (fr) * 1998-10-23 2000-05-04 Yale University La phytomique: une methode genomique de concevoir des compositions a base de plantes
WO2000028090A2 (fr) * 1998-11-12 2000-05-18 Nyxis, Inc. Essais diagnostiques du cancer
WO2000034525A1 (fr) * 1998-12-09 2000-06-15 Vistagen, Inc. Typage de toxicite utilisant des corps embryoides
WO2000039346A1 (fr) * 1998-12-31 2000-07-06 Iconix Pharmaceuticals, Inc. Procede de production d'un systeme marqueur de mecanisme d'action
WO2000043538A1 (fr) * 1999-01-19 2000-07-27 Universite De Montreal Procede de production de banques d'oligonucleotides (ol) representatives de genomes ou d'arnm exprimes (adnc) et leur utilisation
WO2000046404A1 (fr) * 1999-02-05 2000-08-10 Wrair Walter Reed Army Institute Of Research Methode pour diagnostiquer l'exposition a des agents toxiques en mesurant une configuration distincte des niveaux d'expression de genes specifiques
WO2000052209A1 (fr) * 1999-03-02 2000-09-08 Chiron Corporation Microarrays permettant d'identifier l'activation ou l'induction de voies biochimiques
WO2000060124A2 (fr) * 1999-04-06 2000-10-12 Yale University Analyse d'adresses fixes de séquences étiquetées
WO2000063435A2 (fr) * 1999-04-15 2000-10-26 Curagen Corporation Procede d'identification d'agents toxiques au moyen d'une expression genetique differentielle
WO2001002609A2 (fr) * 1999-07-02 2001-01-11 Curagen Corporation Identification d'agents toxiques au moyen d'une l'expression genique differentielle
FR2798392A1 (fr) * 1999-09-13 2001-03-16 Exonhit Therapeutics Sa Marqueurs genetiques de la toxicite, preparation et utilisations
US6228589B1 (en) * 1996-10-11 2001-05-08 Lynx Therapeutics, Inc. Measurement of gene expression profiles in toxicity determination
WO2001036684A2 (fr) * 1999-11-19 2001-05-25 Incyte Genomics, Inc. Marqueurs de reaction toxicologique
WO2001044512A2 (fr) * 1999-12-16 2001-06-21 Curagen Corporation PROCÉDÉS D'IDENTIFICATION DE LIGANDS DU RÉCEPTEUR GAMMA ACTIVÉ PAR LES PROLIFÉRATEURS DE PEROXYSOMES (PPARη) AU MOYEN DE L'EXPRESSION GÉNIQUE DIFFÉRENTIELLE
EP1126035A1 (fr) * 1998-10-30 2001-08-22 Takara Shuzo Co, Ltd. Technique permettant de detecter un gene affecte par un agent perturbateur endocrinien
WO2001066803A2 (fr) * 2000-03-09 2001-09-13 Yale University La phytomique: un procede genomique de concevoir des compositions a base de plantes
WO2001071027A2 (fr) * 2000-03-24 2001-09-27 Micromet Ag Amplification d'arn messager
WO2001096865A1 (fr) * 2000-06-14 2001-12-20 Vistagen, Inc. Typage de toxicite au moyen de cellules souches mesenchymateuses
WO2001096866A1 (fr) * 2000-06-14 2001-12-20 Vistagen, Inc. Typage de toxicite grace a des cellules embryonnaires de foie
US6403778B1 (en) 1998-05-04 2002-06-11 Incyte Genomics, Inc. Toxicological response markers
EP1226280A2 (fr) * 1999-10-25 2002-07-31 Princeton University Sequences genetiques associees a la proliferation et aux pathologies des cellules neuronales
WO2002059357A2 (fr) * 2001-01-24 2002-08-01 Genomic Expression Aps Dosage et kit d'analyse d'expression genique
WO2003008630A2 (fr) * 2001-07-19 2003-01-30 Syngenta Limited Technique d'etablissement du profil d'expression genique et de determination des niveaux de proteines et de metabolites
EP1302546A2 (fr) * 2001-10-10 2003-04-16 Tosoh Corporation Méthode d'évaluation de l'efficacité et de la toxicité des médicaments
EP1392871A2 (fr) * 2001-05-22 2004-03-03 Gene Logic, Inc. Modelisation en toxicologie moleculaire
EP1412537A2 (fr) * 2001-07-10 2004-04-28 Gene Logic, Inc. Modelisation toxicologique moleculaire de la cardiotoxine
WO2004048598A2 (fr) * 2002-11-22 2004-06-10 Gene Logic, Inc. Modelage nephrotoxicologique moleculaire
EP1967592A1 (fr) * 1995-06-07 2008-09-10 Solexa, Inc. Procédé d'amélioration de l'efficacité de séquençage de polynucléotide
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US7469185B2 (en) 2002-02-04 2008-12-23 Ocimum Biosolutions, Inc. Primary rat hepatocyte toxicity modeling
WO2009065355A1 (fr) * 2007-11-16 2009-05-28 Hyk Gene Technology Co., Ltd. Procédé et système de séquençage de l'adn
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
US8003375B2 (en) 1998-03-11 2011-08-23 Exonhit Therapeutics S.A. Qualitative differential screening
EP2387627A1 (fr) * 2009-01-15 2011-11-23 Imdaptive Inc. Profilage d'immunité adaptative et méthodes de génération d'anticorps monoclonaux
EP2495334A1 (fr) * 2009-10-29 2012-09-05 NGK Insulators, Ltd. Procédé de détection d'un acide nucléique cible
US8278044B2 (en) 2008-12-17 2012-10-02 Universiteit Maastricht Method for the identification of carcinogenic compounds
US20140171335A1 (en) * 2007-03-26 2014-06-19 Novartis Ag Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
US20150218620A1 (en) * 2014-02-03 2015-08-06 Integrated Dna Technologies, Inc. Methods to capture and/or remove highly abundant rnas from a heterogenous rna sample
US9150905B2 (en) 2012-05-08 2015-10-06 Adaptive Biotechnologies Corporation Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
US9181591B2 (en) 2011-10-21 2015-11-10 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9217176B2 (en) 2008-11-07 2015-12-22 Sequenta, Llc Methods of monitoring conditions by sequence analysis
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9416420B2 (en) 2008-11-07 2016-08-16 Adaptive Biotechnologies Corp. Monitoring health and disease status using clonotype profiles
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US9512487B2 (en) 2008-11-07 2016-12-06 Adaptive Biotechnologies Corp. Monitoring health and disease status using clonotype profiles
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
US9809813B2 (en) 2009-06-25 2017-11-07 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
US9824179B2 (en) 2011-12-09 2017-11-21 Adaptive Biotechnologies Corp. Diagnosis of lymphoid malignancies and minimal residual disease detection
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
US10077478B2 (en) 2012-03-05 2018-09-18 Adaptive Biotechnologies Corp. Determining paired immune receptor chains from frequency matched subunits
US10150996B2 (en) 2012-10-19 2018-12-11 Adaptive Biotechnologies Corp. Quantification of adaptive immune cell genomes in a complex mixture of cells
US10221461B2 (en) 2012-10-01 2019-03-05 Adaptive Biotechnologies Corp. Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
US10392663B2 (en) 2014-10-29 2019-08-27 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from a large number of samples
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
US11041202B2 (en) 2015-04-01 2021-06-22 Adaptive Biotechnologies Corporation Method of identifying human compatible T cell receptors specific for an antigenic target
US11047008B2 (en) 2015-02-24 2021-06-29 Adaptive Biotechnologies Corporation Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing
US11066705B2 (en) 2014-11-25 2021-07-20 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
US11248253B2 (en) 2014-03-05 2022-02-15 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021944A1 (fr) * 1994-02-14 1995-08-17 Smithkline Beecham Corporation Genes exprimes differemment chez des sujets sains et chez des sujets malades

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021944A1 (fr) * 1994-02-14 1995-08-17 Smithkline Beecham Corporation Genes exprimes differemment chez des sujets sains et chez des sujets malades

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRENNER S., LERNER R. A.: "ENCODED COMBINATORIAL CHEMISTRY.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 89., no. 12., 1 June 1992 (1992-06-01), US, pages 5381 - 5383., XP000647936, ISSN: 0027-8424, DOI: 10.1073/pnas.89.12.5381 *
CHETVERIN A. B., KRAMER F. R.: "OLIGONUCLEOTIDE ARRAYS: NEW CONCEPTS AND POSSIBILITIES.", BIOTECHNOLOGY. THE INTERNATIONAL MONTHLY FOR INDUSTRIAL BIOLOGY, NATURE PUBLISHING GROUP, US, vol. 12., 1 November 1994 (1994-11-01), US, pages 1093 - 1099., XP000606269, ISSN: 0733-222X, DOI: 10.1038/nbt1194-1093 *
MATSUBARA K, OKUBO K: "CDNA ANALYSES IN THE HUMAN GENOME PROJECT", GENE., ELSEVIER, AMSTERDAM., NL, vol. 135, no. 01/02, 15 December 1993 (1993-12-15), NL, pages 265 - 274, XP002947854, ISSN: 0378-1119, DOI: 10.1016/0378-1119(93)90076-F *
See also references of EP0931165A4 *

Cited By (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1967592A1 (fr) * 1995-06-07 2008-09-10 Solexa, Inc. Procédé d'amélioration de l'efficacité de séquençage de polynucléotide
US6228589B1 (en) * 1996-10-11 2001-05-08 Lynx Therapeutics, Inc. Measurement of gene expression profiles in toxicity determination
WO1999027090A1 (fr) * 1997-11-20 1999-06-03 Smithkline Beecham Corporation Procede d'evaluation des effets toxiques et pathologiques de stimuli environnementaux sur la transcription des genes
US8003375B2 (en) 1998-03-11 2011-08-23 Exonhit Therapeutics S.A. Qualitative differential screening
US6403778B1 (en) 1998-05-04 2002-06-11 Incyte Genomics, Inc. Toxicological response markers
WO1999058720A1 (fr) * 1998-05-12 1999-11-18 Acacia Biosciences, Inc. Appareils, systemes et procedes quantitatifs permettant d'analyser une expression genique
WO2000012760A3 (fr) * 1998-08-28 2000-08-03 Incyte Pharma Inc Marqueurs de reaction toxicologique
WO2000012760A2 (fr) * 1998-08-28 2000-03-09 Incyte Pharmaceuticals, Inc. Marqueurs de reaction toxicologique
WO2000014273A3 (fr) * 1998-09-03 2000-06-02 Signalgene Inc Technique de representation de differentiels genetiques et vecteur
WO2000014273A2 (fr) * 1998-09-03 2000-03-16 Signalgene Inc. Technique de representation de differentiels genetiques et vecteur
WO2000015851A1 (fr) * 1998-09-17 2000-03-23 Curagen Corporation Classification geometrique et hierarchique fondee sur l'expression genetique
US6593084B2 (en) 1998-10-13 2003-07-15 Robert E. Bird Carcinogen assay
WO2000022168A1 (fr) * 1998-10-13 2000-04-20 Bioreliance Testing And Development, Inc. Evaluation de cancerogenicite
WO2000024934A1 (fr) * 1998-10-23 2000-05-04 Yale University La phytomique: une methode genomique de concevoir des compositions a base de plantes
EP1126035A1 (fr) * 1998-10-30 2001-08-22 Takara Shuzo Co, Ltd. Technique permettant de detecter un gene affecte par un agent perturbateur endocrinien
EP1126035A4 (fr) * 1998-10-30 2002-09-11 Takara Shuzo Co Technique permettant de detecter un gene affecte par un agent perturbateur endocrinien
WO2000028090A3 (fr) * 1998-11-12 2000-11-16 Nyxis Inc Essais diagnostiques du cancer
WO2000028090A2 (fr) * 1998-11-12 2000-05-18 Nyxis, Inc. Essais diagnostiques du cancer
US6440676B1 (en) 1998-11-12 2002-08-27 Nyxis Neurotherapies, Inc. Diagnostic assay for cancer
WO2000034525A1 (fr) * 1998-12-09 2000-06-15 Vistagen, Inc. Typage de toxicite utilisant des corps embryoides
WO2000039346A1 (fr) * 1998-12-31 2000-07-06 Iconix Pharmaceuticals, Inc. Procede de production d'un systeme marqueur de mecanisme d'action
WO2000043538A1 (fr) * 1999-01-19 2000-07-27 Universite De Montreal Procede de production de banques d'oligonucleotides (ol) representatives de genomes ou d'arnm exprimes (adnc) et leur utilisation
WO2000046404A1 (fr) * 1999-02-05 2000-08-10 Wrair Walter Reed Army Institute Of Research Methode pour diagnostiquer l'exposition a des agents toxiques en mesurant une configuration distincte des niveaux d'expression de genes specifiques
WO2000052209A1 (fr) * 1999-03-02 2000-09-08 Chiron Corporation Microarrays permettant d'identifier l'activation ou l'induction de voies biochimiques
WO2000060124A2 (fr) * 1999-04-06 2000-10-12 Yale University Analyse d'adresses fixes de séquences étiquetées
US6677121B2 (en) 1999-04-06 2004-01-13 Agilix Corporation Fixed address analysis of sequence tags
WO2000060124A3 (fr) * 1999-04-06 2002-01-31 Univ Yale Analyse d'adresses fixes de séquences étiquetées
WO2000063435A3 (fr) * 1999-04-15 2002-09-12 Curagen Corp Procede d'identification d'agents toxiques au moyen d'une expression genetique differentielle
WO2000063435A2 (fr) * 1999-04-15 2000-10-26 Curagen Corporation Procede d'identification d'agents toxiques au moyen d'une expression genetique differentielle
WO2001002609A3 (fr) * 1999-07-02 2002-09-12 Curagen Corp Identification d'agents toxiques au moyen d'une l'expression genique differentielle
WO2001002609A2 (fr) * 1999-07-02 2001-01-11 Curagen Corporation Identification d'agents toxiques au moyen d'une l'expression genique differentielle
WO2001020029A3 (fr) * 1999-09-13 2001-11-29 Exonhit Therapeutics Sa Marquers genetiques de la toxicite, preparation et utilisations
WO2001020029A2 (fr) * 1999-09-13 2001-03-22 Exonhit Therapeutics Sa Marquers genetiques de la toxicite, preparation et utilisations
FR2798392A1 (fr) * 1999-09-13 2001-03-16 Exonhit Therapeutics Sa Marqueurs genetiques de la toxicite, preparation et utilisations
US6509153B1 (en) 1999-09-13 2003-01-21 Exonhit Therapeutics Sa Genetic markers of toxicity preparation and uses
EP1226280A2 (fr) * 1999-10-25 2002-07-31 Princeton University Sequences genetiques associees a la proliferation et aux pathologies des cellules neuronales
EP1226280A4 (fr) * 1999-10-25 2003-10-15 Univ Princeton Sequences genetiques associees a la proliferation et aux pathologies des cellules neuronales
WO2001036684A3 (fr) * 1999-11-19 2002-03-14 Incyte Genomics Inc Marqueurs de reaction toxicologique
WO2001036684A2 (fr) * 1999-11-19 2001-05-25 Incyte Genomics, Inc. Marqueurs de reaction toxicologique
WO2001044512A3 (fr) * 1999-12-16 2002-07-11 Curagen Corp PROCÉDÉS D'IDENTIFICATION DE LIGANDS DU RÉCEPTEUR GAMMA ACTIVÉ PAR LES PROLIFÉRATEURS DE PEROXYSOMES (PPARη) AU MOYEN DE L'EXPRESSION GÉNIQUE DIFFÉRENTIELLE
WO2001044512A2 (fr) * 1999-12-16 2001-06-21 Curagen Corporation PROCÉDÉS D'IDENTIFICATION DE LIGANDS DU RÉCEPTEUR GAMMA ACTIVÉ PAR LES PROLIFÉRATEURS DE PEROXYSOMES (PPARη) AU MOYEN DE L'EXPRESSION GÉNIQUE DIFFÉRENTIELLE
WO2001066803A2 (fr) * 2000-03-09 2001-09-13 Yale University La phytomique: un procede genomique de concevoir des compositions a base de plantes
WO2001066803A3 (fr) * 2000-03-09 2002-04-18 Univ Yale La phytomique: un procede genomique de concevoir des compositions a base de plantes
EP1728874A1 (fr) * 2000-03-24 2006-12-06 Micromet AG Méhode pour la préparation d' un surrogate in vitro pour identifier les gènes exprimés dans un échantillon test
WO2001071027A3 (fr) * 2000-03-24 2003-10-09 Micromet Ag Amplification d'arn messager
WO2001071027A2 (fr) * 2000-03-24 2001-09-27 Micromet Ag Amplification d'arn messager
US7229760B2 (en) 2000-03-24 2007-06-12 Micromet Ag mRNA amplification
US8143009B2 (en) 2000-06-14 2012-03-27 Vistagen, Inc. Toxicity typing using liver stem cells
US8512957B2 (en) 2000-06-14 2013-08-20 Vistagen Therapeutics, Inc. Toxicity typing using liver stem cells
WO2001096865A1 (fr) * 2000-06-14 2001-12-20 Vistagen, Inc. Typage de toxicite au moyen de cellules souches mesenchymateuses
WO2001096866A1 (fr) * 2000-06-14 2001-12-20 Vistagen, Inc. Typage de toxicite grace a des cellules embryonnaires de foie
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
WO2002059357A2 (fr) * 2001-01-24 2002-08-01 Genomic Expression Aps Dosage et kit d'analyse d'expression genique
WO2002059357A3 (fr) * 2001-01-24 2004-03-25 Genomic Expression Aps Dosage et kit d'analyse d'expression genique
US7426441B2 (en) 2001-05-22 2008-09-16 Ocimum Biosolutions, Inc. Methods for determining renal toxins
EP1392871A4 (fr) * 2001-05-22 2006-04-19 Gene Logic Inc Modelisation en toxicologie moleculaire
EP1392871A2 (fr) * 2001-05-22 2004-03-03 Gene Logic, Inc. Modelisation en toxicologie moleculaire
US7415358B2 (en) 2001-05-22 2008-08-19 Ocimum Biosolutions, Inc. Molecular toxicology modeling
EP1412537A2 (fr) * 2001-07-10 2004-04-28 Gene Logic, Inc. Modelisation toxicologique moleculaire de la cardiotoxine
EP1412537A4 (fr) * 2001-07-10 2005-07-27 Gene Logic Inc Modelisation toxicologique moleculaire de la cardiotoxine
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
WO2003008630A3 (fr) * 2001-07-19 2003-07-31 Syngenta Ltd Technique d'etablissement du profil d'expression genique et de determination des niveaux de proteines et de metabolites
WO2003008630A2 (fr) * 2001-07-19 2003-01-30 Syngenta Limited Technique d'etablissement du profil d'expression genique et de determination des niveaux de proteines et de metabolites
EP1302546A3 (fr) * 2001-10-10 2003-11-26 Tosoh Corporation Méthode d'évaluation de l'efficacité et de la toxicité des médicaments
US7049103B2 (en) 2001-10-10 2006-05-23 Tosoh Corporation Method of evaluating drug efficacy and toxicity
EP1302546A2 (fr) * 2001-10-10 2003-04-16 Tosoh Corporation Méthode d'évaluation de l'efficacité et de la toxicité des médicaments
US7469185B2 (en) 2002-02-04 2008-12-23 Ocimum Biosolutions, Inc. Primary rat hepatocyte toxicity modeling
WO2004048598A2 (fr) * 2002-11-22 2004-06-10 Gene Logic, Inc. Modelage nephrotoxicologique moleculaire
WO2004048598A3 (fr) * 2002-11-22 2005-03-31 Gene Logic Inc Modelage nephrotoxicologique moleculaire
US20140171335A1 (en) * 2007-03-26 2014-06-19 Novartis Ag Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
WO2009065355A1 (fr) * 2007-11-16 2009-05-28 Hyk Gene Technology Co., Ltd. Procédé et système de séquençage de l'adn
US9523129B2 (en) 2008-11-07 2016-12-20 Adaptive Biotechnologies Corp. Sequence analysis of complex amplicons
US9512487B2 (en) 2008-11-07 2016-12-06 Adaptive Biotechnologies Corp. Monitoring health and disease status using clonotype profiles
US10760133B2 (en) 2008-11-07 2020-09-01 Adaptive Biotechnologies Corporation Monitoring health and disease status using clonotype profiles
US10266901B2 (en) 2008-11-07 2019-04-23 Adaptive Biotechnologies Corp. Methods of monitoring conditions by sequence analysis
US11001895B2 (en) 2008-11-07 2021-05-11 Adaptive Biotechnologies Corporation Methods of monitoring conditions by sequence analysis
US10246752B2 (en) 2008-11-07 2019-04-02 Adaptive Biotechnologies Corp. Methods of monitoring conditions by sequence analysis
US10155992B2 (en) 2008-11-07 2018-12-18 Adaptive Biotechnologies Corp. Monitoring health and disease status using clonotype profiles
US11021757B2 (en) 2008-11-07 2021-06-01 Adaptive Biotechnologies Corporation Monitoring health and disease status using clonotype profiles
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9217176B2 (en) 2008-11-07 2015-12-22 Sequenta, Llc Methods of monitoring conditions by sequence analysis
US9228232B2 (en) 2008-11-07 2016-01-05 Sequenta, LLC. Methods of monitoring conditions by sequence analysis
US10519511B2 (en) 2008-11-07 2019-12-31 Adaptive Biotechnologies Corporation Monitoring health and disease status using clonotype profiles
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US9347099B2 (en) 2008-11-07 2016-05-24 Adaptive Biotechnologies Corp. Single cell analysis by polymerase cycling assembly
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9416420B2 (en) 2008-11-07 2016-08-16 Adaptive Biotechnologies Corp. Monitoring health and disease status using clonotype profiles
US8278044B2 (en) 2008-12-17 2012-10-02 Universiteit Maastricht Method for the identification of carcinogenic compounds
EP2387627B1 (fr) * 2009-01-15 2016-03-30 Adaptive Biotechnologies Corporation Profilage d'immunité adaptative et méthodes de génération d'anticorps monoclonaux
EP2387627A1 (fr) * 2009-01-15 2011-11-23 Imdaptive Inc. Profilage d'immunité adaptative et méthodes de génération d'anticorps monoclonaux
US10323276B2 (en) 2009-01-15 2019-06-18 Adaptive Biotechnologies Corporation Adaptive immunity profiling and methods for generation of monoclonal antibodies
US11214793B2 (en) 2009-06-25 2022-01-04 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
US9809813B2 (en) 2009-06-25 2017-11-07 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
US11905511B2 (en) 2009-06-25 2024-02-20 Fred Hutchinson Cancer Center Method of measuring adaptive immunity
EP2495334A4 (fr) * 2009-10-29 2013-08-21 Ngk Insulators Ltd Procédé de détection d'un acide nucléique cible
EP2495334A1 (fr) * 2009-10-29 2012-09-05 NGK Insulators, Ltd. Procédé de détection d'un acide nucléique cible
US9175339B2 (en) 2009-10-29 2015-11-03 Ngk Insulators, Ltd. Method for detection of target nucleic acid
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
US9181591B2 (en) 2011-10-21 2015-11-10 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9181590B2 (en) 2011-10-21 2015-11-10 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9279159B2 (en) 2011-10-21 2016-03-08 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9824179B2 (en) 2011-12-09 2017-11-21 Adaptive Biotechnologies Corp. Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
US10077478B2 (en) 2012-03-05 2018-09-18 Adaptive Biotechnologies Corp. Determining paired immune receptor chains from frequency matched subunits
US9371558B2 (en) 2012-05-08 2016-06-21 Adaptive Biotechnologies Corp. Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
US10214770B2 (en) 2012-05-08 2019-02-26 Adaptive Biotechnologies Corp. Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
US9150905B2 (en) 2012-05-08 2015-10-06 Adaptive Biotechnologies Corporation Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
US10894977B2 (en) 2012-05-08 2021-01-19 Adaptive Biotechnologies Corporation Compositions and methods for measuring and calibrating amplification bias in multiplexed PCR reactions
US10221461B2 (en) 2012-10-01 2019-03-05 Adaptive Biotechnologies Corp. Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
US11180813B2 (en) 2012-10-01 2021-11-23 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
US10150996B2 (en) 2012-10-19 2018-12-11 Adaptive Biotechnologies Corp. Quantification of adaptive immune cell genomes in a complex mixture of cells
US10526650B2 (en) 2013-07-01 2020-01-07 Adaptive Biotechnologies Corporation Method for genotyping clonotype profiles using sequence tags
US10077473B2 (en) 2013-07-01 2018-09-18 Adaptive Biotechnologies Corp. Method for genotyping clonotype profiles using sequence tags
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
US20150218620A1 (en) * 2014-02-03 2015-08-06 Integrated Dna Technologies, Inc. Methods to capture and/or remove highly abundant rnas from a heterogenous rna sample
US11248253B2 (en) 2014-03-05 2022-02-15 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
US11261490B2 (en) 2014-04-01 2022-03-01 Adaptive Biotechnologies Corporation Determining antigen-specific T-cells
US10435745B2 (en) 2014-04-01 2019-10-08 Adaptive Biotechnologies Corp. Determining antigen-specific T-cells
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
US10392663B2 (en) 2014-10-29 2019-08-27 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from a large number of samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
US11066705B2 (en) 2014-11-25 2021-07-20 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
US11047008B2 (en) 2015-02-24 2021-06-29 Adaptive Biotechnologies Corporation Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing
US11041202B2 (en) 2015-04-01 2021-06-22 Adaptive Biotechnologies Corporation Method of identifying human compatible T cell receptors specific for an antigenic target
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements

Similar Documents

Publication Publication Date Title
US6228589B1 (en) Measurement of gene expression profiles in toxicity determination
WO1997013877A1 (fr) Mesure de profils d'expression genique pour evaluer la toxicite
US5763175A (en) Simultaneous sequencing of tagged polynucleotides
US5780231A (en) DNA extension and analysis with rolling primers
US6172214B1 (en) Oligonucleotide tags for sorting and identification
US6140489A (en) Compositions for sorting polynucleotides
EP1967592B1 (fr) Procédé d'amélioration de l'efficacité de séquençage de polynucléotide
EP0832287B1 (fr) Marqueurs oligonuclotidiques servant a trier et a identifier
US6280935B1 (en) Method of detecting the presence or absence of a plurality of target sequences using oligonucleotide tags
US5654413A (en) Compositions for sorting polynucleotides
JP4105764B2 (ja) 毒性決定における遺伝子発現プロフィールの測定
EP0840803B1 (fr) Sequencage simultane de polynucleotides marques
JP4789294B2 (ja) ローリングプライマーを用いたｄｎａ伸長および分析

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CZ EE FI HU JP KR LT LV NO NZ PL RU SG US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Free format text: US ET AL.

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97515240

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996940238

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996940238

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09269911

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996940238

Country of ref document: EP